Eravacycline
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Eravacycline |
| DrugBank ID | DB12329 |
| Brand Names (EU) | Xerava |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 96.85% |
Approved Indication (EMA)
Xerava is indicated in adolescents from the age of 12 years weighing at least 50 kg, and in adults, for the treatment of complicated intra-abdominal infections (cIAI). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | bronchitis | 96.85% | DL |
| 2 | laryngotracheitis | 86.51% | DL |
| 3 | bronchial neoplasm (disease) | 85.97% | DL |
| 4 | conjunctivitis | 85.88% | DL |
| 5 | sclerosing cholangitis | 84.42% | DL |
| 6 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | 77.54% | DL |
| 7 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | 77.46% | DL |
| 8 | brain small vessel disease 1 with or without ocular anomalies | 76.50% | DL |
| 9 | diabetic nephropathy | 76.05% | DL |
| 10 | rheumatoid arthritis | 73.27% | DL |
| 11 | rhinitis | 72.99% | DL |
| 12 | pityriasis simplex | 72.64% | DL |
| 13 | obstructive lung disease | 72.27% | DL |
| 14 | irritable bowel syndrome | 71.68% | DL |
| 15 | infective urethral stricture | 71.63% | DL |
| 16 | conjunctivitis (disease) | 71.31% | DL |
| 17 | hyperthyroidism | 71.28% | DL |
| 18 | post-bacterial disorder | 70.39% | DL |
| 19 | postinfectious vasculitis | 70.22% | DL |
| 20 | Chagas cardiomyopathy | 69.72% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.